These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

88 related items for PubMed ID: 492058

  • 21. [Use of the Doppler for intrafemoral injection in arteritis].
    Van der Molen HR, Toth LM, Collard JJ, Balmus KJ.
    Phlebologie; 1979; 32(1):67-73. PubMed ID: 432292
    [Abstract] [Full Text] [Related]

  • 22. [Experiences with Trental in peripheral circulatory disorders and cerebrovascular insufficiency (author's transl)].
    Schafé MK.
    Munch Med Wochenschr; 1973 Oct 05; 115(40):1745-9. PubMed ID: 4801042
    [No Abstract] [Full Text] [Related]

  • 23. [Long-term results of the treatment of arteritis with intra-arterial injections using Reboul's technique].
    Van der Molen HR, Toth LM, Collard JJ, Balmus KJ.
    Phlebologie; 1979 Oct 05; 32(1):57-65. PubMed ID: 432291
    [Abstract] [Full Text] [Related]

  • 24. [Survey on adherence to hygiene and dietary rules in patients with arterial occlusive disease].
    Aligne C, Mosnier M, Mistretta F, Larguier JS.
    J Mal Vasc; 2000 Jun 05; 25(3):187-94. PubMed ID: 10906634
    [Abstract] [Full Text] [Related]

  • 25. Clinical evaluation of flunarizine: walking distance, ergometric performance, and hemodynamic and biochemical effects.
    Rudofsky G, Brock FE, Ulrich M, Nobbe F.
    Angiology; 1979 Jul 05; 30(7):470-9. PubMed ID: 380410
    [No Abstract] [Full Text] [Related]

  • 26. [Methods and results of controlled walking training in patients with peripheral arterial occlusive disease].
    Cachovan M.
    Z Arztl Fortbild Qualitatssich; 1999 Nov 05; 93(9):626-32. PubMed ID: 10666825
    [Abstract] [Full Text] [Related]

  • 27. Clinical and circulatory effects of Iloprost either administered for 1 week or 4 weeks in patients with peripheral obstructive arterial disease at Leriche-Fontaine stage III.
    Arosio E, Sardina M, Prior M, De Marchi S, Zannoni M, Bianchini C.
    Eur Rev Med Pharmacol Sci; 1998 Nov 05; 2(2):53-9. PubMed ID: 10229559
    [Abstract] [Full Text] [Related]

  • 28. [Evaluation of cutaneous necrosis risk in peripheral arterial diseases].
    D'Eri A, Martini R, Cordova RM, Trevisan G, Andreozzi GM.
    Minerva Cardioangiol; 2002 Jun 05; 50(3):239-44. PubMed ID: 12107403
    [Abstract] [Full Text] [Related]

  • 29. [Treatment of chronic arterial occlusive disease. Clinical study with a new galenic preparation of Pentoxifyllin (Trental 400) (author's transl)].
    Angelkort B, Doppelfeld E.
    Med Klin; 1978 May 26; 73(21):791-7. PubMed ID: 651768
    [Abstract] [Full Text] [Related]

  • 30. Success of an outpatient claudication group training program for patients with peripheral arterial occlusive disease (PAOD): the Tübingen model.
    Klyscz T, Jünger M, Jünger I, Hahn M, Rassner G.
    Cent Eur J Public Health; 1997 Mar 26; 5(1):13-20. PubMed ID: 9150999
    [Abstract] [Full Text] [Related]

  • 31. [Ambulatory physical therapy rehabilitation with interval walking-gymnastics therapy in patients with chronic peripheral arterial occlusive disease].
    Mederacke W, Winterfeld HJ, Schmidt HH.
    Z Gesamte Inn Med; 1988 May 15; 43(10):265-8. PubMed ID: 3046157
    [Abstract] [Full Text] [Related]

  • 32. [Therapy of peripheral arterial occlusive disease with special reference to prostaglandins].
    Creutzig A.
    Z Gesamte Inn Med; 1991 Mar 15; 46(3):59-67. PubMed ID: 1828125
    [Abstract] [Full Text] [Related]

  • 33. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial.
    Dal Lago A, De Martini D, Flore R, Gaetani E, Gasbarrini A, Gerardino L, Pola R, Santoliquido A, Serricchio M, Tondi P, Nolfe G.
    Drugs Exp Clin Res; 1999 Mar 15; 25(1):29-36. PubMed ID: 10337502
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Therapy of chronic arterial occlusive disease. Studies with an orally administered drug under ambulatory conditions].
    Wampola H.
    Fortschr Med; 1977 May 12; 95(18):1240,1242-5. PubMed ID: 405291
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Treatment of peripheral occlusive vascular disease with pentoxifylin (author's transl)].
    Traumann KJ.
    Med Klin; 1976 Mar 12; 71(11):465-8. PubMed ID: 1263995
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Minimal walking distance following exercise treatment in patients with arterial occlusive disease.
    Rosetzsky A, Struckmann J, Mathiesen FR.
    Ann Chir Gynaecol; 1985 Mar 12; 74(6):261-4. PubMed ID: 4096478
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.